Results 171 to 180 of about 129,997 (236)

Consumer attitudes, willingness to pay and hedonic evaluations of innovative legume gnocchi products

open access: yesJournal of the Science of Food and Agriculture, Volume 105, Issue 5, Page 2867-2878, 30 March 2025.
Abstract BACKGROUND With growing concerns over the adverse effects of animal‐derived products on health, animal welfare and the environment, the rising popularity of plant‐based foods underscores the importance of understanding consumer preferences and determining acceptance.
Muhammad Adzran Che Mustapa   +5 more
wiley   +1 more source

Demand‐Driven Mergers: Advertising, Differentiation, and Welfare

open access: yesManagerial and Decision Economics, EarlyView.
ABSTRACT We consider mergers that induce demand changes. We study the firms' incentives to submit a merger request and the competition authority's decision to approve the request. We show that merger‐induced demand changes help expand settings where the interests of firms and competition authority align, whereas contexts where their interests are ...
Felix Munoz‐Garcia   +2 more
wiley   +1 more source

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

open access: yesNeuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy